title: Hypertension: an unstudied potential risk factor for adverse outcomes during continuous flow ventricular assist device support.
abstract: In end-stage heart failure, left ventricular assist devices (LVADs) represent an exciting new frontier in which post-device implantation survival approaches that of heart transplant. However, expansion of this technology is still limited by complications that impact morbidity and mortality. Thus, it is essential to identify and optimize modifiable predictors of poor outcomes. One such predictor may be hypertension (HTN). Not only may chronic HTN as a traditional cardiovascular risk factor be present during long-term LVAD support, but HTN may also contribute to device malfunction or device-associated complications. Although current guidelines identify blood pressure (BP) control as important to outpatient continuous flow (CF) LVAD management, there is no evidence base to support these guidelines. Indeed, our comprehensive literature search did not identify any studies that evaluated post-device implantation HTN as a potential predictor of adverse CF-LVAD outcomes. HTN among CF-LVAD patients is likely a relatively unstudied factor because of difficulties using standard noninvasive techniques to measure BP in the setting of reduced pulsatile flow. Fortunately, recent research has elucidated the meaning of Doppler BP measurements and validated a slow-cuff deflation system for BP measurements in the setting of CF-LVAD support. Therefore, CF-LVAD researchers and clinicians may (1) consider potential mechanisms relating HTN to poor outcomes, (2) realize that HTN management is a stated goal despite scarce evidence, and (3) utilize the new reliable and valid methods for outpatient BP measurement that make research and management possible. It is critical and now feasible that research on HTN in the CF-LVAD patient population move forward.
authors.affiliation: NewYork-Presbyterian, Columbia University Medical Center, 622 West 168th Street, PH12-134, New York, NY, 10032-3720, USA.
authors.forename: Lauren T
authors.initials: LT
authors.lastname: Wasson
authors.forename: Melana
authors.initials: M
authors.lastname: Yuzefpolskaya
authors.forename: Michiyori
authors.initials: M
authors.lastname: Wakabayashi
authors.forename: Hiroo
authors.initials: H
authors.lastname: Takayama
authors.forename: Yoshifumi
authors.initials: Y
authors.lastname: Naka
authors.forename: Nir
authors.initials: N
authors.lastname: Uriel
authors.forename: Ulrich P
authors.initials: UP
authors.lastname: Jorde
authors.forename: Ryan T
authors.initials: RT
authors.lastname: Demmer
authors.forename: Paolo C
authors.initials: PC
authors.lastname: Colombo
mesh_terms: D006333:Heart Failure / Q000150:complications* / Q000628:therapy*; D016027:Heart Transplantation; D006353:Heart-Assist Devices / Q000009:adverse effects*; D006801:Humans; D006973:Hypertension; D011379:Prognosis; D012307:Risk Factors; D016896:Treatment Outcome